Disclaimer: statistics are based on job posting analysis and do not represent the actual situation of current employees; system stability may affect objectivity, so please treat the data as reference only.Data inaccurate? Report it

Education requirement: 高中 is the most common

51% 高中 24.5% 大专 14.3% 本科 10.2% 不限

What education does Hubei Kaixiang Pharmaceutical Co., Ltd. require? 高中占比最多，占51%，大专占24.5%，本科占14.3%，不限占10.2%

Salary by education

Note: Hubei Kaixiang Pharmaceutical Co., Ltd. salaries by education, 大专 ¥26.1K, to see salaries for other education levels, click the detail page

Experience requirement: 不限 is the most common

44.9% 1-3年 2% 3-5年 53.1% 不限

Does Hubei Kaixiang Pharmaceutical Co., Ltd. require much experience? 不限 accounts for 53.1% (the largest share), 1-3年 accounts for 44.9%, 3-5年 accounts for 2%

Salary by experience

Note: Hubei Kaixiang Pharmaceutical Co., Ltd. salaries by experience, 1-3年 ¥7.6K, 3-5年 ¥12.5K, 不限 ¥16.1K

staff structure: 销售类 is the most common

销售类 100%(49) 򀀩

医疗卫生/美容保健类 40.8%(20) 򀀩

Which departments does Hubei Kaixiang Pharmaceutical Co., Ltd. have? 销售类 is the most common, accounting for 100%, 医疗卫生/美容保健类 accounts for 40.8%, . Based on job postings in the past year. For reference only.

Salaries for hot jobs of

Are salaries high at Hubei Kaixiang Pharmaceutical Co., Ltd.? We provide: 医药代表, 临床, 地区经理, 大区经理, 学术专员, 药学, 销售, 学术经理. Click to view detailed salary analysis by job.

Work locations at : mainly 襄阳, 十堰

襄阳￥12.6K 14.3%(7) 򀀩

十堰￥13.8K 10.2%(5) 򀀩

荆门 10.2%(5) 򀀩

Note: in which cities does Hubei Kaixiang Pharmaceutical Co., Ltd. have offices? The main distribution is as follows: 襄阳 accounts for 14.3%, 十堰 accounts for 10.2%, 荆门 accounts for 10.2%, based on job postings in the past year. For reference only.

How is the growth outlook for the company?

Regional distribution of positions over the years

14 2021 5 2023 11 2024 16 2025 8 2026

Employment outlook for Hubei Kaixiang Pharmaceutical Co., Ltd.: in 2026, Hubei Kaixiang Pharmaceutical Co., Ltd. had openings in 8 regions , 8 fewer than in 2025